nitrendipine has been researched along with nicotine in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.00) | 18.7374 |
| 1990's | 4 (20.00) | 18.2507 |
| 2000's | 9 (45.00) | 29.6817 |
| 2010's | 6 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Keserü, GM | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Baraldi, PG; Geppetti, P; Materazzi, S; Preti, D | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Hayashi, S; Kato, A; Mizuno, K; Morita, A; Nakata, E; Ohashi, K; Yamamura, K | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aunis, D; Gandía, L; García, AG; Ladona, MG | 1 |
| Damaj, MI; Martin, BR; Welch, SP | 1 |
| Czirfuzs, A; Fleckenstein-Grün, G; Frey, M; Matyas, S; Thimm, F | 1 |
| Damaj, MI | 1 |
| Koizumi, S; Moriyama, Y; Ogura, A; Yamada, H; Yamaguchi, A | 1 |
| Jeong, MS; Kim, CJ; Kim, KW; Park, EY; Park, JW; Shin, BS; Shin, MS; Woo, RS; Zhao, RJ | 1 |
1 review(s) available for nitrendipine and nicotine
| Article | Year |
|---|---|
Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Asthma; Humans; Ion Channel Gating; Neurons; Pain; Peripheral Nervous System Diseases; Pulmonary Disease, Chronic Obstructive; Transient Receptor Potential Channels | 2010 |
19 other study(ies) available for nitrendipine and nicotine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
Topics: Analgesics; Animals; Benzimidazoles; Drug Design; Drug Evaluation, Preclinical; Humans; Microsomes, Liver; Neuralgia; Nociceptin Receptor; Pyrroles; Rats; Receptors, Opioid; Structure-Activity Relationship | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Dihydropyridine modulation of the chromaffin cell secretory response.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Animals; Cats; Cell Membrane Permeability; Chromaffin Granules; Chromaffin System; Female; Male; Muscarine; Nicotine; Nitrendipine; Norepinephrine; Perfusion; Potassium; Pyridines | 1987 |
Involvement of calcium and L-type channels in nicotine-induced antinociception.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Analgesia; Animals; Behavior, Animal; Calcimycin; Calcium; Calcium Channel Blockers; Calcium Channels; Injections, Spinal; Intracellular Fluid; Kinetics; Male; Mecamylamine; Mice; Mice, Inbred ICR; Nicotine; Nitrendipine; Nociceptors; Pain Measurement; Rats; Receptors, Nicotinic; Terpenes; Thapsigargin; Tritium | 1993 |
Experimental vasoprotection by calcium antagonists against calcium-mediated arteriosclerotic alterations.
Topics: Adult; Aged; Aged, 80 and over; Animals; Arteriosclerosis; Calcium; Calcium Channel Blockers; Cells, Cultured; Cholecalciferol; Cholesterol; Coronary Vessels; Diltiazem; Disease Models, Animal; Humans; Hypertension; Middle Aged; Muscle, Smooth, Vascular; Nicotine; Nifedipine; Nitrendipine; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Sprague-Dawley; Risk Factors; Verapamil | 1994 |
Altered behavioral sensitivity of Ca(2+)-modulating drugs after chronic nicotine administration in mice.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Analgesics; Animals; Behavior, Animal; Binding Sites; Brain; Calcium; Calcium Channels; Drug Tolerance; Ion Transport; Male; Mice; Mice, Inbred ICR; Motor Activity; Nicotine; Nitrendipine; Thapsigargin; Tritium | 1997 |
Acetylcholine triggers L-glutamate exocytosis via nicotinic receptors and inhibits melatonin synthesis in rat pinealocytes.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Acetylcholine; Animals; Arylamine N-Acetyltransferase; Atropine; Bungarotoxins; Calcium; Calcium Channel Agonists; Calcium Channel Blockers; Calcium Channels; Calcium Channels, L-Type; Carbachol; Cells, Cultured; Diltiazem; Exocytosis; Glutamic Acid; Melatonin; Muscarine; Muscarinic Agonists; Muscarinic Antagonists; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Nifedipine; Nitrendipine; Oxotremorine; Parasympathetic Nervous System; Pineal Gland; Rats; Rats, Wistar; Receptors, Nicotinic; Scopolamine; Synaptic Vesicles; Tubocurarine | 1998 |
Mechanism of nicotine-evoked release of 3H-noradrenaline in human cerebral cortex slices.
Topics: Adolescent; Adult; Arginine; Calcium; Calcium Channel Blockers; Cerebral Cortex; Dihydro-beta-Erythroidine; Dizocilpine Maleate; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fluoxetine; Ganglionic Stimulants; Guanylate Cyclase; Humans; In Vitro Techniques; Indazoles; Male; Mecamylamine; Methylene Blue; Neuroprotective Agents; NG-Nitroarginine Methyl Ester; Nicotine; Nicotinic Antagonists; Nitrendipine; Nitric Oxide Synthase; Norepinephrine; omega-Conotoxin GVIA; Oxadiazoles; Purinones; Quinoxalines; Tetrodotoxin; Tritium; Tubocurarine | 2002 |